Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating brivaracetam as monotherapy in children and adolescents with childhood absence epilepsy or juvenile absence epilepsy has compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Childhood Absence Epilepsy
• Juvenile Absence Epilepsy

Drugs mentioned

• BRIVARACETAM (brivaracetam)

Snippet

Sponsor: UCB Biopharma SRL | Conditions: Childhood Absence Epilepsy, Juvenile Absence Epilepsy | Phase 3 | Status: COMPLETED